After intravenous administration of sodium fluorescein is rapidly distributed in the body and reaches the retina after a few seconds.
The binding to plasma proteins
in the plasma of 50 – 84% of the winstrol depot drug binds to proteins (especially albumin), and about 15-17% -. With red blood cells
after administration of sodium fluorescein the skin of the patient temporarily acquires a yellowish tint which disappears after 6-12 hours.
In the body, the drug is rapidly metabolized to the glucuronide fluorescein, also having fluorescent properties. After 4-5 hours after administration of the drug found in plasma mainly as the glucuronide. Glucuronic less metabolite associated with plasma proteins than fluorescein.
final half-life of sodium fluorescein and its metabolite plasma-glucuronic approximately 23.5 and 264 min, respectively.
Over 48 hours there is an almost complete (90%) withdrawing sodium fluorescein and its metabolites in the bile and urine. The drug in the urine is determined for 24-36 hours with a gradual decrease in its concentration. At 24-36 hours after administration of sodium fluorescein observed bright yellow color of urine.
In patients with diabetes fluorescein sodium winstrol depot pharmacokinetic parameters are not changed.
- Fluorescein angiography of the fundus and of the iris vasculature. The drug is intended for diagnostic purposes only.
- Hypersensitivity to fluorescein sodium or any other component of the formulation;
- Intrathecal or intra-arterial administration.
Clinical studies on the use of Fluorescein Novartis solution in children and adolescents under 18 years have not been conducted.
Caution should be exercised when using the drug in patients with allergy or bronchial asthma in history.
When the need for fluorescein angiography in patients with intolerance to other angiographic dye or severe allergic reactions in history, should be very carefully relate anticipated benefits of research and the potential risk of severe allergies, which can be fatal .
Clinical studies on the use of winstrol depot solution in children and adolescents under 18 years have not been conducted.
Pregnancy and lactation
The potential risk to the fetus during in pregnant women is unknown. The drug should not be used during pregnancy unless the expected benefit from the research to the mother outweighs the potential risk to the fetus. Fluorescein sodium is excreted in breast milk. It is necessary to abandon breastfeeding within .
Dosing and Administration Adults 5 ml of the drug (1 vial) administered intravenously.
Elderly patients do not need medication dosing regimen correction.
Children and adolescents
Clinical studies on the use solution in children and adolescents under 18 years have not been conducted. This category of patients is recommended to prescribe the drug on the basis of, for example -5 mg / kg.
The most common adverse winstrol depot reactions with the use of the drug are nausea and vomiting.
Allergic Reactions: Hypersensitivity development, manifested by skin reactions (urticaria), and in rare cases – anaphylactic / anaphylactoid shock which can be fatal.
From the central and peripheral nervous system: loss of consciousness, convulsions, impairment of cerebral circulation, headache, dizziness.
Cardio-vascular system: arterial hypotension, chest pain, heart failure, acute myocardial infarction and severe shock.
The respiratory system: dyspnea, laryngeal edema, bronchospasm.